1. Thery C, Witwer KW, Aikawa E, et al. Minimal information for studies of extracellular vesicles 2018 (MISEV2018): a position statement of the International Society for Extracellular Vesicles and update of the MISEV2014 guidelines. J Extracell Vesicles. 2018;7(1):1535750
2. Alvar J, Vélez ID, Bern C, et al. Leishmaniasis worldwide and global estimates of its incidence. PloS One. 2012;7(5):e35671.
3. Aronson N, Herwaldt BL, Libman M, et al. Diagnosis and treatment of leishmaniasis: clinical practice guidelines by the Infectious Diseases Society of America (IDSA) and the American Society of Tropical Medicine and Hygiene (ASTMH). Clin Infect Dis. 2016;63(12):e202-e64.
4. Nemati S, Fazaeli A, Hajjaran H, et al. Genetic diversity and phylogenetic analysis of the Iranian Leishmania parasites based on HSP70 gene PCR-RFLP and sequence analysis. Korean J Parasitol. 2017; 55(4):367-374.
5. Rostamian M, Bashiri H, Yousefinejad V, et al. Prevalence of human visceral leishmaniasis in Iran: A systematic review and meta-analysis. Comp Immunol Microbiol Infect Dis. 2021; 75:101604.
6. Madusanka RK, Silva H, Karunaweera ND. Treatment of cutaneous leishmaniasis and insights into species-specific responses: a narrative review. Infect Dis Therapy. 2022;11(2):695-711.
7. WHO. Leishmaniasis, Neglected tropical diseases. 2022. https://www.who.int/data/gho/data/themes/topics/gho-ntd-leishmaniasis. (accessed 2021).
8. Hajjaran H, Saberi R, Borjian A, et al. The geographical distribution of human cutaneous and visceral Leishmania species identified by molecular methods in Iran: a systematic review with meta-analysis. Front Public Health. 2021;9: 661674.
9. Razavi MR, Shirzadi MR, Mohebali M, et al. Human Cutaneous Leishmaniosis in Iran, Up to Date-2019. J Arthropod Borne Dis. 2021;15(2):143-151.
10. Sabzevari S, Teshnizi SH, Shokri A, et al. Cutaneous leishmaniasis in Iran: A systematic review and meta-analysis. Microb Pathog. 2021;152:104721.
11. López L, Robayo M, Vargas M. Thermotherapy. An alternative for the treatment of American cutaneous leishmaniasis. Trials. 2012;13:58.
12. Mohammad N, Sagheer F, Paracha MM, et al. Comparison Of Efficacy Of Miltefosine Versus Meglumine Antimonate In The Treatment Of Cutaneous Leishmaniasis. J Ayub Med College, JAMC. 2022;34(4):849-53.
13. Ponte-Sucre A, Gamarro F, Dujardin J-C, et al. Drug resistance and treatment failure in leishmaniasis: A 21st century challenge. PLoS Negl Trop Dis. 2017;11(12):e0006052.
14. Eskandari SE, Khamesipour A, Jaafari MR, et al. Combination of topical liposomal amphotericin B and Glucantime in comparison with glucantime alone for the treatment of anthroponotic cutaneous leishmaniasis (ACL). Iranian J Microb. 2021;13(5):718-23.
15. Mohtasebi S, Mohebali M, Elikaee S, et al. In vitro and in vivo anti-parasitic activity of biogenic antimony sulfide nanoparticles on Leishmania major (MRHO/IR/75/ER). Parasitol Res. 2019;118(9):2669-78.
16. Bayat F, Hosseinpour R, Mehryab F, et al. Potential application of liposomal nanodevices for non-cancer diseases: an update on design, characterization and biopharmaceutical evaluation. Adv Colloid Interface Sci. 2020;277:102121.
17. Ghorbani M, Farhoudi R. Leishmaniasis in humans: drug or vaccine therapy? Drug Des Devel Ther. 2018; 12:25-40.
18. Akbari M, Oryan A, Hatam G. Application of nanotechnology in treatment of leishmaniasis: a review. Acta Trop. 2017;172:86-90.
19. Coakley G, Maizels RM, Buck AH. Exosomes and other extracellular vesicles: the new communicators in parasite infections. Trend Parasitol. 2015;31(10):477-89.
20. Dong G, Filho AL, Olivier M. Modulation of host-pathogen communication by extracellular vesicles (EVs) of the protozoan parasite Leishmania. Front Cell Infect Microb. 2019;9:100.
21. Mehryab F, Rabbani S, Shahhosseini S, et al. Exosomes as a next-generation drug delivery system: an update on drug loading approaches, characterization, and clinical application challenges. Acta Biomater. 2020;113:42-62.
22. Soleymani M, Saberi S, Shekari F. Extracellular vesicles in regenerative medicine, a brief review. Modern Med Lab J. 2019;2(2):118-26.
23. Rai A, Fang H, Fatmous M, et al. A protocol for isolation, purification, characterization, and functional dissection of exosomes. Methods Mol Biol. 2021:2261:105-149.
24. Brennan K, Martin K, FitzGerald S.P, et al. A comparison of methods for the isolation and separation of extracellular vesicles from protein and lipid particles in human serum. Sci Rep. 2020;10(1):1039.
25. Heidari S, Hajjaran H, Kazemi B, et al. Identification of immunodominant proteins of Leishmania infantum by immunoproteomics to evaluate a recombinant multi-epitope designed antigen for serodiagnosis of human visceral leishmaniasis. Exp Parasitol. 2021;222:108065.
26. Mardpour S, Ghanian MH, Sadeghi-Abandansari H, et al. Hydrogel-mediated sustained systemic delivery of mesenchymal stem cell-derived extracellular vesicles improves hepatic regeneration in chronic liver failure. ACS Appl Mater Interfaces. 2019;11(41):37421-33.
27. Seyedrazizadeh S-Z, Poosti S, Nazari A, et al. Extracellular vesicles derived from human ES-MSCs protect retinal ganglion cells and preserve retinal function in a rodent model of optic nerve injury. Stem Cell Res Ther. 2020;11(1):203.
28. Parvez S, Yadagiri G, Gedda MR, et al. Modified solid lipid nanoparticles encapsulated with Amphotericin B and Paromomycin: an effective oral combination against experimental murine visceral leishmaniasis. Sci Rep. 2020;10(1): 12243.
29. Abu Ammar A, Nasereddin A, Ereqat S, et al. Amphotericin B-loaded nanoparticles for local treatment of cutaneous leishmaniasis. Drug Deli Trans Res. 2019;9(1):76-84.
30. Salehi-Sangani G, Mohebali M, Jajarmi V, et al. Immunization against Leishmania major infection in BALB/c mice using a subunit-based DNA vaccine derived from TSA, LmSTI1, KMP11, and LACK predominant antigens. Iran J Basic Med Sci. 2019;22(12):1493-1501.
31. Mehrizi TZ, Ardestani MS, Molla Hoseini MH, et al. Novel nano-sized chitosan amphotericin B formulation with considerable improvement against Leishmania major. Nanomedicine. 2018;13(24):3129-47.
32. Shirzadi MR. Lipsosomal amphotericin B: a review of its properties, function, and use for treatment of cutaneous leishmaniasis. Res Rep Trop Med. 2019; 10:11-18.
33. WHO. Regional Office for the Eastern Mediterranean‎. Manual for case management of cutaneous leishmaniasis in the WHO Eastern Mediterranean Region. https://apps.who.int/iris/handle/10665/120002. (accessed 2014).
34. Asad M, Bhattacharya P, Banerjee A. Therapeutic and immunomodulatory activities of short-course treatment of murine visceral leishmaniasis with KALSOME™ 10, a new liposomal amphotericin B. BMC Infect Dis. 2015;15:188.
35. Sundar S, Chakravarty J, Meena LP. Leishmaniasis: treatment, drug resistance and emerging therapies. Expert Opin Orphan Drug. 2019;7(1):1-10.
36. Bunggulawa EJ, Wang W, Yin T, et al. Recent advancements in the use of exosomes as drug delivery systems. J Nanobiotechnology. 2018;16(1):18.
37. Carrera-Bravo C, Koh EY, Tan KS. The roles of parasite-derived extracellular vesicles in disease and host-parasite communication. Parasitol Int. 2021;83:102373.
38. Pérez-Cabezas B, Santarém N, Cecílio P, et al. More than just exosomes: distinct Leishmania infantum extracellular products potentiate the establishment of infection. J Extracell Vesicles. 2018;7(1):1541708.
39. Kanchanapally R, Deshmukh SK, Chavva SR, et al. Drug-loaded exosomal preparations from different cell types exhibit distinctive loading capability, yield, and antitumor efficacies: a comparative analysis. Int J Nanomedicine. 2019;11:531-41.
40. Ebrahimian M, Hashemi M, Etemad L, et al. Thymoquinone-loaded mesenchymal stem cell-derived exosome as an efficient nano-system against breast cancer cells. Iran J Basic Med Sci. 2022;25(6):723-31.
41. Mishra J, Dey A, Singh N, Somvanshi R, et al. Evaluation of toxicity & therapeutic efficacy of a new liposomal formulation of amphotericin B in a mouse model. Indian J Med Res. 2013;137(4):767-76.